The Stroop test validation in the detection of minimal hepatic encephalopathy in Mexican patients with cirrhosis, preliminary results
Minimal hepatic encephalopathy (MHE) is an important cause of morbi-mortality in patients with cirrhosis; its timely identification has an impact on prognosis; the Stroop Test is a diagnostic tool that can be useful and practical in these patients. Validating this test and calculating the cut-off po...
Saved in:
Published in | Annals of hepatology Vol. 27; p. 100785 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier España, S.L.U
01.12.2022
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Minimal hepatic encephalopathy (MHE) is an important cause of morbi-mortality in patients with cirrhosis; its timely identification has an impact on prognosis; the Stroop Test is a diagnostic tool that can be useful and practical in these patients. Validating this test and calculating the cut-off point for the diagnosis of MHE in our population is important. This study aimed to validate the Stroop Test application and estimate the cut-off point for the diagnosis of MHE in our population.
Observational, cross-sectional and prolective study to validate and calculate the cut-off point of the Stroop Test; patients with cirrhosis with and without manifest hepatic encephalopathy will be included, who will undergo the Stroop Test, psychometric score of hepatic encephalopathy (PHES) and the critical flicker frequency test (CFF): ROC curves will be calculated to measure sensitivity, specificity and its cut-off point, healthy subjects will also be included for comparison. The trial was approved by the research ethics committee, and informed consent was obtained.
One hundred subjects participated: 50 controls, 33 females (66%) age =43.2±12.1 years; and 50 patients with hepatic cirrhosis: 27 females (54%) age 53.2±8.2 years, of which 54%, 42% and 2% were in Child-Pugh A, B and C, respectively. AUROC was calculated for patients with cirrhosis with and without MHE, AUROC= 0.751 (CI=0.656-.846); cut-off point=183.5 sensitivity (SE)=60% specificity (SP)=74% (Figure 1).
For our study sample, we found that the Stroop Test is a good diagnostic tool, taking into account a cut-off point of 183.5 sec. as opposed to 274.9 sec. that the apple application gives us, which is validated in a different population (grade and quality of education).
Donation by the volunteer ladies of the Hospital General de México “Dr. Eduardo Liceaga.”
The authors declare no potential conflicts of interest. |
---|---|
AbstractList | Introduction and Objectives: Minimal hepatic encephalopathy (MHE) is an important cause of morbi-mortality in patients with cirrhosis; its timely identification has an impact on prognosis; the Stroop Test is a diagnostic tool that can be useful and practical in these patients. Validating this test and calculating the cut-off point for the diagnosis of MHE in our population is important. This study aimed to validate the Stroop Test application and estimate the cut-off point for the diagnosis of MHE in our population. Materials and Methods: Observational, cross-sectional and prolective study to validate and calculate the cut-off point of the Stroop Test; patients with cirrhosis with and without manifest hepatic encephalopathy will be included, who will undergo the Stroop Test, psychometric score of hepatic encephalopathy (PHES) and the critical flicker frequency test (CFF): ROC curves will be calculated to measure sensitivity, specificity and its cut-off point, healthy subjects will also be included for comparison. The trial was approved by the research ethics committee, and informed consent was obtained. Results: One hundred subjects participated: 50 controls, 33 females (66%) age =43.2±12.1 years; and 50 patients with hepatic cirrhosis: 27 females (54%) age 53.2±8.2 years, of which 54%, 42% and 2% were in Child-Pugh A, B and C, respectively. AUROC was calculated for patients with cirrhosis with and without MHE, AUROC= 0.751 (CI=0.656-.846); cut-off point=183.5 sensitivity (SE)=60% specificity (SP)=74% (Figure 1). Conclusions: For our study sample, we found that the Stroop Test is a good diagnostic tool, taking into account a cut-off point of 183.5 sec. as opposed to 274.9 sec. that the apple application gives us, which is validated in a different population (grade and quality of education). Funding: Donation by the volunteer ladies of the Hospital General de México “Dr. Eduardo Liceaga.” Declaration of interest: The authors declare no potential conflicts of interest. Introduction and ObjectivesMinimal hepatic encephalopathy (MHE) is an important cause of morbi-mortality in patients with cirrhosis; its timely identification has an impact on prognosis; the Stroop Test is a diagnostic tool that can be useful and practical in these patients. Validating this test and calculating the cut-off point for the diagnosis of MHE in our population is important. This study aimed to validate the Stroop Test application and estimate the cut-off point for the diagnosis of MHE in our population. Materials and MethodsObservational, cross-sectional and prolective study to validate and calculate the cut-off point of the Stroop Test; patients with cirrhosis with and without manifest hepatic encephalopathy will be included, who will undergo the Stroop Test, psychometric score of hepatic encephalopathy (PHES) and the critical flicker frequency test (CFF): ROC curves will be calculated to measure sensitivity, specificity and its cut-off point, healthy subjects will also be included for comparison. The trial was approved by the research ethics committee, and informed consent was obtained. ResultsOne hundred subjects participated: 50 controls, 33 females (66%) age =43.2±12.1 years; and 50 patients with hepatic cirrhosis: 27 females (54%) age 53.2±8.2 years, of which 54%, 42% and 2% were in Child-Pugh A, B and C, respectively. AUROC was calculated for patients with cirrhosis with and without MHE, AUROC= 0.751 (CI=0.656-.846); cut-off point=183.5 sensitivity (SE)=60% specificity (SP)=74% (Figure 1). ConclusionsFor our study sample, we found that the Stroop Test is a good diagnostic tool, taking into account a cut-off point of 183.5 sec. as opposed to 274.9 sec. that the apple application gives us, which is validated in a different population (grade and quality of education). FundingDonation by the volunteer ladies of the Hospital General de México “Dr. Eduardo Liceaga.” Declaration of interestThe authors declare no potential conflicts of interest. Minimal hepatic encephalopathy (MHE) is an important cause of morbi-mortality in patients with cirrhosis; its timely identification has an impact on prognosis; the Stroop Test is a diagnostic tool that can be useful and practical in these patients. Validating this test and calculating the cut-off point for the diagnosis of MHE in our population is important. This study aimed to validate the Stroop Test application and estimate the cut-off point for the diagnosis of MHE in our population. Observational, cross-sectional and prolective study to validate and calculate the cut-off point of the Stroop Test; patients with cirrhosis with and without manifest hepatic encephalopathy will be included, who will undergo the Stroop Test, psychometric score of hepatic encephalopathy (PHES) and the critical flicker frequency test (CFF): ROC curves will be calculated to measure sensitivity, specificity and its cut-off point, healthy subjects will also be included for comparison. The trial was approved by the research ethics committee, and informed consent was obtained. One hundred subjects participated: 50 controls, 33 females (66%) age =43.2±12.1 years; and 50 patients with hepatic cirrhosis: 27 females (54%) age 53.2±8.2 years, of which 54%, 42% and 2% were in Child-Pugh A, B and C, respectively. AUROC was calculated for patients with cirrhosis with and without MHE, AUROC= 0.751 (CI=0.656-.846); cut-off point=183.5 sensitivity (SE)=60% specificity (SP)=74% (Figure 1). For our study sample, we found that the Stroop Test is a good diagnostic tool, taking into account a cut-off point of 183.5 sec. as opposed to 274.9 sec. that the apple application gives us, which is validated in a different population (grade and quality of education). Donation by the volunteer ladies of the Hospital General de México “Dr. Eduardo Liceaga.” The authors declare no potential conflicts of interest. |
ArticleNumber | 100785 |
Author | Santana Vargas, AD Domínguez Cardoso, PF Higuera de la Tijera, F Montemira Orozco, D Pérez Hernández, JL Hinojosa Segura, CI |
Author_xml | – sequence: 1 givenname: PF surname: Domínguez Cardoso fullname: Domínguez Cardoso, PF – sequence: 2 givenname: JL surname: Pérez Hernández fullname: Pérez Hernández, JL – sequence: 3 givenname: F surname: Higuera de la Tijera fullname: Higuera de la Tijera, F – sequence: 4 givenname: AD surname: Santana Vargas fullname: Santana Vargas, AD – sequence: 5 givenname: D surname: Montemira Orozco fullname: Montemira Orozco, D – sequence: 6 givenname: CI surname: Hinojosa Segura fullname: Hinojosa Segura, CI |
BookMark | eNqFUdtu1DAQtVCR2Ba-gBd_ALu1J4ntCIGEKi6VinhoebaMPSEOaRzZaWE_oP_NZBfxgIT6ZHlmzpk555yykylNyNhLKXZSSHU-7Fzqcd6BAKCK0KZ5wjagmnbbtAZO2EYq1WxBGfmMnZYyCFFXjYQNe7jpkV8vOaWZL1gWfu_GGNwS08TjxBfqBlzQHwqp47dxirdu5LSNhjzHyePcuzHRt9-vkM_4K3o38bWP01L4z7j03Mec-1RiecXnjGMkHpf3PGO5G5fynD3t3FjwxZ_3jH398P7m4tP26svHy4t3V1tfSbq_RSN8F6QHrP23UIngVKVJSpAGmrYOBoSRIIRQbQOqU7rWFTQKOmm0AV2dscsjb0husHMmKXlvk4v2UEj5u3WZZI1oVe3aILQCMK7GzrTKCBM06qC1clgTV3Xk8jmVkrH7yyeFXVOxgz2kYtdU7DEVQr05opBk3kfMtvi4mhhiJpfpjvgI_u0_eD9SJN6NP3CPZUh3eSIHrbQFrLDXa-5r7ECuSNBABK__T_Do-t9w48HP |
ContentType | Journal Article |
Copyright | 2022 |
Copyright_xml | – notice: 2022 |
DBID | 6I. AAFTH AAYXX CITATION DOA |
DOI | 10.1016/j.aohep.2022.100785 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2659-5982 |
EndPage | 100785 |
ExternalDocumentID | oai_doaj_org_article_64a9d076228a4ef896808d7e7d776ae4 10_1016_j_aohep_2022_100785 S1665268122001272 1_s2_0_S1665268122001272 |
GroupedDBID | --- .1- .FO 0R~ 1P~ 23M 2WC 53G 5GY 77H AAEDW AAKDD AALRI AAXUO AAYWO ABXHO ACVFH ADBBV ADCNI ADVLN AENEX AEUPX AEVXI AEXQZ AFJKZ AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APOWU APXCP BAWUL EBD EBS EMOBN F5P FDB GROUPED_DOAJ GX1 M41 OC. OK1 ON0 P2P ROL RSH SV3 TR2 Z5R AFCTW DIK NCXOZ 0SF 6I. AAFTH AAYXX CITATION |
ID | FETCH-LOGICAL-c3165-9e80cfd1c2e4cbd30da637043d182594d82081200069526f674732562f1878273 |
IEDL.DBID | DOA |
ISSN | 1665-2681 |
IngestDate | Wed Aug 27 01:31:58 EDT 2025 Tue Jul 01 00:53:21 EDT 2025 Thu Jul 20 20:10:30 EDT 2023 Sun Feb 23 10:19:46 EST 2025 Tue Aug 26 16:40:56 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | http://creativecommons.org/licenses/by-nc-nd/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3165-9e80cfd1c2e4cbd30da637043d182594d82081200069526f674732562f1878273 |
OpenAccessLink | https://doaj.org/article/64a9d076228a4ef896808d7e7d776ae4 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_64a9d076228a4ef896808d7e7d776ae4 crossref_primary_10_1016_j_aohep_2022_100785 elsevier_sciencedirect_doi_10_1016_j_aohep_2022_100785 elsevier_clinicalkeyesjournals_1_s2_0_S1665268122001272 elsevier_clinicalkey_doi_10_1016_j_aohep_2022_100785 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | December 2022 |
PublicationDateYYYYMMDD | 2022-12-01 |
PublicationDate_xml | – month: 12 year: 2022 text: December 2022 |
PublicationDecade | 2020 |
PublicationTitle | Annals of hepatology |
PublicationYear | 2022 |
Publisher | Elsevier España, S.L.U Elsevier |
Publisher_xml | – name: Elsevier España, S.L.U – name: Elsevier |
SSID | ssj0043512 |
Score | 2.2979715 |
Snippet | Minimal hepatic encephalopathy (MHE) is an important cause of morbi-mortality in patients with cirrhosis; its timely identification has an impact on prognosis;... Introduction and ObjectivesMinimal hepatic encephalopathy (MHE) is an important cause of morbi-mortality in patients with cirrhosis; its timely identification... Introduction and Objectives: Minimal hepatic encephalopathy (MHE) is an important cause of morbi-mortality in patients with cirrhosis; its timely... |
SourceID | doaj crossref elsevier |
SourceType | Open Website Index Database Publisher |
StartPage | 100785 |
SubjectTerms | Gastroenterology and Hepatology |
Title | The Stroop test validation in the detection of minimal hepatic encephalopathy in Mexican patients with cirrhosis, preliminary results |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1665268122001272 https://www.clinicalkey.es/playcontent/1-s2.0-S1665268122001272 https://dx.doi.org/10.1016/j.aohep.2022.100785 https://doaj.org/article/64a9d076228a4ef896808d7e7d776ae4 |
Volume | 27 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07T-QwELYQxYkGwXGI5XFyQUnExnHspAQEQkhLwyHRWdl4rA1aklUSJPgB_G9m7ARtcTqaa6P4kZmx55t4_A1jpwi5Ic3TLHJlLiMqdR9lKo4jcLgjQ5q41NFF4dm9un2Ud0_p01qpL8oJC_TAQXDnSha5xWBbiKyQ4LKcakVYDdpqrQrwTKDo88ZgKuzBiAHCOafyOVxZPPIN-cyuolkAUVUK4XMEqIzymk_y1P1rrmnN3dzssO0BJ_KLML9dtgH1T_ZjNpyE77EP1C9_6BH3rjiixZ6jxVShPhKvao6wjlvofZ5VzRvHiULkBTvEORFHK6cFvVoUy4ZKEr9Tkxm80ZbIB6bVjtMvWl5Wbbtouqo746sWlr4GWPvOMUh_XfbdL_Z4c_3n6jYaSipEZRKjLHLIpqWzcSlAlnObTG2hEo3yshhnpLm0CAjQ5ZMTy1OhnMJoI0FUJFycIZbQyT7brJsaDhiXMpeIHqy2aSkLjR3PtQL0h3MENdpmE3Y2CtWsAnOGGVPKno3XgSEdmKCDCbskwX-9SrTX_gEagxmMwXxnDBMmR7WZ8WYp7oXYUfXvsfXfmkE3rOfOxKYTZmoeyKDInoTwZ_ZiwtRXywGyBCjy3ZCH_-Nzj9gWdRmya47ZZt--wglipH7-2y-HT8CNDBw |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Stroop+test+validation+in+the+detection+of+minimal+hepatic+encephalopathy+in+Mexican+patients+with+cirrhosis%2C+preliminary+results&rft.jtitle=Annals+of+hepatology&rft.au=Dom%C3%ADnguez+Cardoso%2C+PF&rft.au=P%C3%A9rez+Hern%C3%A1ndez%2C+JL&rft.au=Higuera+de+la+Tijera%2C+F&rft.au=Santana+Vargas%2C+AD&rft.date=2022-12-01&rft.pub=Elsevier+Espa%C3%B1a%2C+S.L.U&rft.issn=1665-2681&rft.eissn=2659-5982&rft.volume=27&rft_id=info:doi/10.1016%2Fj.aohep.2022.100785&rft.externalDocID=S1665268122001272 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F16652681%2FS1665268122X00082%2Fcov150h.gif |